Particle.news

Health ❯Healthcare ❯Genetics ❯Genetic Disorders

Cardiovascular Disease

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

Terms of Service Privacy Policy Jobs Help Partners About Us

Copyright © 2025 Mina Labs Inc.